Oncol Res Treat. 2017;40(9):540-546. doi: 10.1159/000477095. Epub 2017 Aug 17.
Adoptive transfer of chimeric antigen receptor-engineered T cells (CARTs) is a novel approach to cancer therapy as CARTs combine with the antigen specificity of an antibody and the activating functions of T lymphocytes. Recent results from preclinical and clinical trials with CARTs for B-cell malignancies are exciting, although different groups selected different tumor-associated antigens, binding domains, and signal domains, which make up the chimeric antigen receptor (CAR) configuration. However, there are few clinical trials with CARTs for solid tumors compared to hematologic malignancies. In this brief review, we discuss the basic principles of CAR design and clinical studies of CARTs for solid tumors.
嵌合抗原受体修饰的 T 细胞（CART）的过继转移是一种癌症治疗的新方法，因为 CART 结合了抗体的抗原特异性和 T 淋巴细胞的激活功能。尽管不同的研究组选择了不同的肿瘤相关抗原、结合域和信号域，构成嵌合抗原受体（CAR）结构，但目前用 CART 治疗 B 细胞恶性肿瘤的临床前和临床试验结果令人兴奋。然而，与血液系统恶性肿瘤相比，用 CART 治疗实体瘤的临床试验较少。在这篇简要综述中，我们讨论了 CAR 设计的基本原则和 CART 治疗实体瘤的临床研究。
